Company news
Curis, Inc. (NASDAQ:CRIS) news
Curis, Inc. news releases on 6ix. Latest, Sep 2, 2026: Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World…
Press releases & updates
Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
September 2, 2026
Curis, Inc. Announces Pricing of $5.6 Million Public Offering
August 13, 2026
Curis Doses First Five Patients in TakeAim CLL Study
July 30, 2026
Curis Announces Positive Emavusertib Update
July 22, 2026
Curis Consents First Six Patients in TakeAim CLL Study
July 6, 2026
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
June 26, 2026
Curis Provides First Quarter 2026 Business Update
May 12, 2026
Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
May 5, 2026
Curis Provides Fourth Quarter 2025 Business Update
March 19, 2026
Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026
March 12, 2026
Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
January 9, 2026
Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
January 7, 2026
Curis Provides Updated Data from its Frontline AML Triplet Study
December 9, 2025
Curis to Present at Upcoming 30th Annual SNO Meeting
November 14, 2025
Curis Provides Third Quarter 2025 Business Update
November 6, 2025
Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025
October 30, 2025
Curis Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
October 6, 2025
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 3, 2025
Curis to Present at Upcoming Healthcare Conferences in September
September 2, 2025
Curis Provides Second Quarter 2025 Business Update
August 5, 2025
Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025
July 29, 2025
Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement
July 2, 2025
Curis Provides First Quarter 2025 Business Update
May 6, 2025
Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025
April 29, 2025
Curis to Present at Upcoming Healthcare Conference in April
April 2, 2025
Curis Provides Fourth Quarter 2024 Business Update
March 31, 2025
Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025
March 28, 2025
Curis Provides Third Quarter 2024 Business Update
November 13, 2024
Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement
October 28, 2024
Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer
September 22, 2024
Curis Provides Second Quarter 2024 Financial and Operating Update
July 31, 2024
Curis Announces Additional Data from TakeAim Leukemia Study
May 13, 2024
Curis Provides First Quarter 2024 Business Update
May 6, 2024
Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024
April 29, 2024
Curis Provides Fourth Quarter 2023 Business Update
February 7, 2024
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024
January 31, 2024
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
December 11, 2023
Curis Announces Three Presentations at ASH
December 5, 2023
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
December 4, 2023
Curis Provides Third Quarter 2023 Business Update
November 1, 2023
Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023
October 25, 2023
Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer
September 11, 2023
Curis Provides Second Quarter 2023 Business Update
August 2, 2023
Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023
July 26, 2023
Curis Announces $15.1 Million Registered Direct Offering
July 5, 2023
Curis Provides First Quarter 2023 Business Update
May 3, 2023
Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call
March 7, 2023
Curis to Release Fourth Quarter 2022 Financial Results and Hold Conference Call on March 9, 2023
March 1, 2023
Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS
December 11, 2022
Curis Provides Third Quarter 2022 Business Update
November 8, 2022